Selvita Shares Q1 2026 Milestones and Financial Insights
I'm telling you, Selvita's latest report is tighter than a drum. They just dropped their Q1 2026 financial results, showing us a peek into their world of drug discovery and development. Overall, it's been a bit of a mixed bag, but there's plenty of action to grip onto. Picture this – their operating revenue hit EUR 19.1 million, straddling the top end of their forecasts. But peel back the layers, and you'll find a company figuring out its next big play.
Drug Discovery: Weathering the Storm
Let's mosey over to the Drug Discovery segment for a sec. Revenues shrank, sliding down from EUR 15.6 million to EUR 11.6 million compared to the previous year. The EBITDA took a bit of a nosedive too, resting at EUR 1.0 million, almost half of what it was in Q1 2025. Seems like there's a struggle going on across the European landscape for outsourced drug services. They're feeling the pinch from delays and market turbulence. But don't count them out just yet. They still see the seeds of growth beginning to sprout, eyeing new pipeline opportunities.
Drug Development: Climbing the Ladder
Swinging over to the Drug Development segment, where things are starting to heat up. Commercial revenues climbed by 6% year-over-year, reaching a cool EUR 6.2 million. It's no small feat to maintain momentum, and Selvita's pulling it off. Their EBITDA stands at EUR 1.7 million, managing a tiny yet reassuring leap upwards compared to last year. The outlook here is where they’re banking on future prosperity. They’re doubling down on developing advanced modalities to keep that growth engine chugging along.
The CEO himself highlighted the potential lurking in their developments, asserting that they're on the cusp of aligning with market demands.
Unpacking the Strategic Review
Now, the real kicker – Selvita is opening the books for a strategic options review. This is their move to explore ways of fattening that shareholder value long-term. They're casting a wide net here, considering everything from going private to ramping up M&A activities and pouring some new capital into high-yield projects. It’s the kind of review where the sky can be the limit, but they’re keeping mum on specific timelines.
Rothschild & Co is in their corner, advising throughout this journey. CEO Boguslaw Sieczkowski has thrown down the gauntlet, indicating that the current market undervalues their potential, particularly in drug development.
A Glimpse into the Future
You’ve got to admire Selvita’s artistry in weaving a future-focused tapestry. They’re sinking almost half of an EUR 26.4 million grant into upping their Drug Discovery tech. From 2026 to 2029, it's going to be full-steam ahead in the most expansive program they've tackled yet. They're setting up advanced AI tech and pimping out their lab spaces in Kraków, bolstered by an intricate mix of grants, loans, and pocket change.
All told, Selvita sits on a 2026 backlog of EUR 58.1 million. They're not just twiddling their thumbs either – EUR 19.4 million of that is in the ramping Drug Development wing.
The Calm Before the Storm?
So, what’s the takeaway here? Selvita's story is one of cautious optimism. They've put on the brakes on costs, chopping EUR 1.5 million out of the Q1 operating budget, and they’re keeping a vigilant eye on the wider market. There’s an air of transformation, and they’re positioning themselves to ride the next biotechnology crest.
If you ask me, this is a company that understands the importance of playing the long game. They’re not just reacting; they’re crafting their own narrative to walk us through the changing seasons in the biotech world. Let’s watch how they steer this ship in the coming quarters.
